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Abstract
Retroviral integrases (IN) catalyze the integration of the reverse-transcribed viral DNA into the 
host genome, an essential process leading to virus replication. For Moloney murine leukemia virus 
(M-MuLV) IN, the limited solubility of the recombinant protein has restricted the development of 
biophysical and structural analyses. Herein, recombinant M-MuLV IN proteins, either full length 
or two nonoverlapping domain constructs, were purified under non-denaturing conditions from 
solubilized bacterial extracts by Ni2+-NTA resins. Additionally, WT IN was further purified by 
heparin chromatography. All of the purified proteins were shown to be active and stable. WT M-
MuLV IN chromatographed with a peak corresponding with a dimer by gel filtration 
chromatography. In contrast, the single point mutant C209A IN migrated predominantly as a 
tetramer. For both proteins, fractions in equilibrium between dimers and tetramers were competent 
to assemble concerted two-end integrations and yielded a unique strand-transfer profile in the 
presence of a 28-mer U5 oligonucleotide substrate, indicative of a distinct conformation within the 
synaptic complex. This specific target-site selection was not observed with a shorter 20-mer U5 
substrate. These studies provide the foundation for biophysical and structural analysis on M-
MuLV IN and the mechanism of retroviral integration.
Introduction
An essential step of the retroviral life cycle is the integration of the reverse-transcribed viral 
DNA into the host genome. This two-step process is carried out by the viral enzyme 
integrase (IN), encoded by the pol gene. First, two deoxynucleotides are removed from both 
3′ termini of the viral long terminal repeats (LTRs), exposing the conserved CA at the 
recessed 3′ ends (3′-processing) (Brown et al., 1989; Fujiwara and Mizuuchi, 1988; 
Katzman et al., 1989; Roth et al., 1989). The 3′ ends of the viral DNA are then joined to 5′ 
staggered sites in the target DNA in a concerted transesterification reaction (strand transfer) 
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(Craigie et al., 1990; Engelman et al., 1991; Katz et al., 1990). Integration is completed by 
repair of the 5′ overhang of the viral LTR and the single-strand gaps flanking the integrated 
viral DNA, presumably by host enzymes. Repair of the single-strand gaps creates the 
hallmark duplication of the target DNA sequence flanking the retroviral integration site.
Sequence comparison and mutational analysis have identified three functional domains in 
the retroviral IN proteins. The N-terminal domain contains a conserved His-His/Cys-Cys 
(HHCC) region (Johnson et al., 1986), which can coordinate a zinc ion in an ordered 
conformation with increased α-helical content (Burke et al., 1992; McEuen et al., 1992; 
Yang et al., 1999a). For Moloney murine leukemia virus (M-MuLV), the HHCC is essential 
for IN function in vivo and optimal integration in vitro (Jonsson et al., 1996; Roth et al., 
1990). Biophysical and biochemical analyses showed that the HHCC domain is involved in 
protein multimerization (Lee et al., 1997; Yang et al., 1999a; Zheng et al., 1996) and it is 
required for the formation of stable IN–LTR complexes (Donzella et al., 1996; Engelman et 
al., 1993; VanDenEnt et al., 1999; Vink et al., 1994). For M-MuLV IN, we have previously 
shown that the isolated HHCC domain forms dimers in solution (Yang et al., 1999a). 
Preincubation of the isolated M-MuLV HHCC domain with the LTR substrate increases the 
efficiency of two-end concerted integration products, in a complementation assay with a 
core/C-terminus IN construct (Yang and Roth, 2001).
The central core domain of IN is characterized by a conserved D-D(35)-E triad motif. 
Mutation of the conserved aspartic or glutamic acid residues results in loss of all catalytic 
activities, indicating a role for these three residues in active site function (Drelich et al., 
1992; Engelman and Craigie, 1992; Kulkosky et al., 1992; Leavitt et al., 1993). Solution of 
crystal structures of isolated catalytic core domains of human immunodeficiency virus type 
1 (HIV-1) and avian sarcoma virus (ASV) IN revealed that the catalytic domains of 
retroviral INs fold with similar topology (Bujacz et al., 1995; Dyda et al., 1994). Recently, 
structures of the core plus the C-terminus domains of HIV-1 IN (Chen et al., 2000a) and 
HIV-1 core with the N-terminal HHCC domains (Wang et al., 2001) have been solved. In 
these models, the catalytic triad is on the outer faces of the dimer.
The C-terminal region is less conserved and has been demonstrated to possess nonspecific 
DNA-binding activity (Khan et al., 1991; Mumm and Grandgenett, 1991; Vink et al., 1993; 
Woerner and Marcus-Sekura, 1993). The NMR structure of the DNA-binding domain of 
HIV-1 IN appears as a saddle-shaped dimer (Lodi et al., 1995), and the two-domain structure 
with the catalytic core shows flexibility of the C-terminus domain with respect to the 
catalytic core (Chen et al., 2000a, 2000b).
Although the independently folding domains of IN have been delineated and some of their 
structures solved, the manner in which these domains interact to form the catalytically active 
protein is still not understood. Evidence that integrase is a multimeric enzyme has been 
obtained through direct physical measurement of purified IN, cross-linking experiments 
(Gao et al., 2001; Heuer and Brown, 1998), and in vitro complementation analyses 
(Engelman et al., 1993; Jonsson et al., 1996; vanGent et al., 1993; Yang et al., 1999a; Yang 
and Roth, 2001). Purified recombinant INs can exist in a dynamic equilibrium that includes 
monomers, dimers, tetramers, and higher-order oligomers (Bao et al., 2003; Jones et al., 
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1992; Sherman and Fyfe, 1990; Vincent et al., 1993). Sedimentation analysis of ASV IN 
along with activity assays has revealed that the enzyme is active as a multimer, minimally a 
dimer which assembles to a tetramer in the presence of DNA (Bao et al., 2003; Jones et al., 
1992). For M-MuLV integrase, the limited solubility of the recombinant protein has impeded 
structural analyses and detailed studies of subunit composition.
Multiple strategies have been developed to purify retro-viral INs due to their limited 
solubility. The expression and purification of isolated IN regions have facilitated the 
biochemical and biophysical characterization of isolated domains. Full-length, recombinant 
M-MuLV IN proteins required extraction from insoluble fractions under harsh denaturing 
conditions followed by slow refolding schemes of renaturation (Jonsson et al., 1993). 
Structural studies of HIV-1, Rous sarcoma virus (RSV), and simian immunodeficiency virus 
(SIV) INs have been greatly advanced through the mutational analysis of hydrophobic 
residues for improved solubility. For each, one point mutation improved the solubility and 
facilitated structural studies, including F185K for HIV-1 (Jenkins et al., 1996), F199K for 
RSV (Hyde et al., 1999), and F185H for SIV (Li et al., 1999).
In this study, recombinant tagged M-MuLV integrase proteins were purified under 
nondenaturing conditions from solubilized bacterial extracts. All of the purified IN proteins 
were shown to be active and stable in solution. Size fractionation of wild-type (WT) and a 
single point mutant C209A identified multimerization states competent to assemble 
concerted two-end integrations. These studies provide the foundation for structural analysis 
on M-MuLV integrase and retroviral integration.
Results
M-MuLV IN constructs
A schematic representation of the M-MuLV IN and mutants utilized in this study is shown in 
Fig. 1A. Previous work in our laboratory has shown functional complementation between 
two nonoverlapping IN domains, consisting of the HHCC domain (IN 1–105) and the 
core/C-terminal region (IN 106–404) (Yang et al., 1999a; Yang and Roth, 2001). 
Recombinant, purified C209A IN is active using in vitro oligonucleotide-based assays 
(Jonsson et al., 1996); however, in vivo, passage of virions bearing IN C209A are extremely 
delayed (Donzella et al., 1998). Modification of Cys209 with N-ethylmaleimide (NEM) 
blocked IN function and complementation with IN 1–105. C209A IN was insensitive to 
modification with NEM (Donzella et al., 1998) and resulted in the loss of complementation 
with IN 1–105 (Jonsson et al., 1996). M-MuLV C209A IN was included in these studies due 
to the implication of the central cysteine residue in IN multimerization.
Studies of the HIV-1 (Jenkins et al., 1996), RSV (Hyde et al., 1999), and SIV (Li et al., 
1999) IN proteins have been greatly advanced through the mutational analysis of 
hydrophobic residues for improved solubility. The Genthreader program (Jones, 1999) was 
applied to align and thread the M-MuLV IN against a known IN structure for steric analysis. 
By this approach, A252 within M-MuLV IN was identified as the equivalent to HIV-1 IN 
F185, and N254 was found to be equivalent to RSV IN F199 (data not shown). These 
residues were targeted for mutagenesis (Fig. 1A): Ala252 was replaced by His and Lys; 
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N254 was mutated to Lys. Additionally, a third substitution was generated within a region of 
high hydrophobicity to replace Leu244 to Gln.
Characterization of M-MuLV IN and mutants from the soluble fraction
Fig. 2 shows a schematic of the expression and purification procedure utilized to obtain 
purified WT M-MuLV IN from solubilized bacterial extracts. A similar approach has been 
recently used to express and purify HTLV-2 IN (Pieper and Jonsson, 2002) and the Sin 
Nombre virus N protein (Jonsson et al., 2001), a member of the hantavirus genera, family 
Bunyaviridae. Overnight bacterial cultures were diluted and induced with IPTG for 2 h at 
30°C. Bacterial pellets were resuspended in a solubilization buffer containing 300 mM NaCl 
and 10 mM of the zwitterionic Chaps detergent. Bacterial lysis was triggered at 4°C by 
lysozyme, Dounce homogenization, and extensive but controlled sonication cycles at 4°C. 
Sonication in the presence of Chaps and high salt released IN proteins from cellular nucleic 
acid into a soluble fraction. The soluble fraction was clarified by centrifugation and analyzed 
for solubility or subjected to further purification as discussed below.
Analysis of the solubility of WT and mutant M-MuLV IN
Four mutations, A252H, A242K, N254K, and L244Q, were introduced into M-MuLV IN 
within the region homologous to that which resulted in increased solubility for the HIV-1 
(Jenkins et al., 1996), RSV (Hyde et al., 1999), and SIV (Li et al., 1999) IN proteins (Fig. 
1A). The solubility of these four point-mutant proteins and C209A IN were compared to that 
of the WT IN protein in the context of the current solubilization conditions. Cultures were 
induced with IPTG and lysed, and soluble fractions were obtained under conditions similar 
to those for purifying the wild-type protein (Fig. 2). A representative Western blot of SDS– 
PAGE of the soluble fractions from the different mutants and the parental WT IN is shown 
in Fig. 1B. The 45-kDa protein corresponding to M-MuLV IN was visible in the soluble 
fraction and induced in the presence of IPTG (compare control pET11C (lane 1) to WT IN 
(lane 7)). The 45-kDa protein detected in the L244Q, A252H, A252K, and N254L IN 
mutants was comparable to the WT IN (lanes 2–5). Interestingly, the migration of IN A252H 
was altered compared to the related IN A252K substitution (compare lane 4 to lane 3). A 
small increase in the level of 45-kDa IN was detected in the soluble fraction of C209A IN 
when compared with that of the WT IN protein (compare lanes 6 and 7). This was further 
analyzed in a large-scale purification of the proteins (see below). Western blot analysis 
identified two additional faster migrating species. These are predicted to be N-terminal 
truncations, as they did not bind to Ni+2 NTA affinity columns (see below).
Purification of M-MuLV IN and subdomains from the soluble fraction
The soluble fraction was isolated after clarification by centrifugation and was subjected to 
two different purification schemes, one utilizing batch purification and the other FPLC 
column chromatography (Fig. 2). In order to obtain highly purified full-length IN protein, 
the soluble fraction was applied to a Ni2+-NTA resin column using a FPLC system (Fig. 2, 
right). After washing the column, proteins were eluted with a linear imidazole gradient. 
Fractions were subjected to SDS-PAGE and assayed for strand-transfer activity. This assay 
uses a 5′-labeled oligonucleotide substrate mimicking the U5 LTR terminus, which lacks the 
two terminal bases removed during 3′-processing, thus exposing the 5′-CA-3′ end, as 
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illustrated in Fig. 3A. A representative profile of activity of the eluted fractions from the 
Ni2+-NTA column is shown in Fig. 4A. The predominant protein detected within the peak of 
integrase activity (fractions 21–25) was the 45-kDa IN product, visualized by Coomassie 
staining (Fig. 4A, lower panel). The peak of strand-transfer activity corresponded with 100 
mM imidazole. Although the bulk of eluted IN protein shows a significant level of 
purification, pooled fractions were subjected to further purification through a FPLC–heparin 
resin. Bound proteins were then subjected to elution by a linear gradient of NaCl (0.4–2 M, 
Fig. 2) and fractions were assayed by strand-transfer activity and SDS–PAGE of the 
fractions. A representative column profile of WT IN activity is shown in Fig. 4B. There is a 
sharper peak of strand-transfer activity (i.e., fractions 12–18, upper panel) at 1.1 M NaCl 
which correlates with the elution of the protein as visualized by Coomassie staining (i.e., 
fractions 12–19, Fig. 4B, bottom panel). Furthermore, a smaller protein contaminant eluted 
prior to the 45-kDa IN protein peak. The active WT IN fractions were pooled giving a yield 
of 0.83 mg of highly purified active protein per liter of induced bacterial culture.
Rapid purification of multiple constructs was obtained using batch purification on Ni2+-
NTA. Fig. 4C summarizes the purified fractions of IN 1–105, IN 106–404, C209A IN, and 
WT IN. Fractions were bound in batch to Ni2+-NTA and eluted at 50, 100, 250, and 500 mM 
imidazole steps. Fractions were pooled based on purity across the individual steps. For IN 1–
105 (Fig. 4C, lane 1), C209A IN (Fig. 4C, lane 3), and WT IN (Fig. 4C, lane 4), fractions 
were pooled from the 50 and 100 mM imidazole steps. For IN 106–404, the fractions were 
pooled from the 50–250 mM steps (Fig. 4C, lane 2). Two additional proteins of Mr 26,000 
and 15,000 are detected in the IN 106–404 preparation. The 15-kDa protein was recognized 
by anti-IN antibodies on Western blot (data not shown) and therefore represents a low level 
of breakdown product. Starting from 1 L of induced cultures, this purification scheme yield 
3 mg of IN 1–105, 1.65 mg of IN 106–404, 0.3 mg of C209A IN, and 0.15 mg of WT IN. 
These fractions were suitable for the biochemical studies on the M-MuLV IN proteins 
presented below.
Catalytic properties of the purified IN proteins
Functional complementation between two nonoverlapping fragments of M-MuLV IN, the 
HHCC N-terminal domain (IN 1–105), and the core/C-terminal region (IN 106–404) is 
observed in vitro (Yang et al., 1999a; Yang and Roth, 2001). The purified IN proteins used 
for those studies were extracted from the insoluble fractions followed by slow steps of 
renaturation (Jonsson et al., 1993). To examine the activity of the protein subdomains 
purified from the soluble fraction, the activity of the nonoverlapping domains was 
determined in a complementation assay for the 3′-processing reaction. In this assay, a 20-
mer 5′-labeled blunt-ended oligonucleotide mimicking the terminal U5 at the LTR is used as 
the substrate for the reaction (Fig. 3A). Upon resolution of the products on denaturing 
electrophoresis, both a −2 processed product migrating larger than the input substrate and 
heterogeneous sized strand-transfer products migrating larger than the input substrate can be 
visualized. Fig. 5A shows a complementation assay in which the catalytic subunit of IN (IN 
106–404) was held constant with a titration of the N-terminal domain (IN 1–105) in the 
reaction. No products were detected in the absence of enzyme (Fig. 5A, lane 1) or in the 
presence of IN 106–404 alone (Fig. 5A, lane 3). Upon addition of the HHCC domain (for a 
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molar ratio IN 1–105:IN 106–404 of 2.3), both the 3′-processing and the strand-transfer 
products can be visualized (Fig. 5A, lane 4). Higher levels of the HHCC domain in the 
reaction inhibited catalysis (lanes 5–9). Optimal activity was observed at 10 mM MnCl2 and 
100 mM of KCl. A low level of strand-transfer activity was observed in 1 mM of MgCl2 
(data not shown).
The catalytic activity of the nonoverlapping IN fragments was also assayed for concerted 
two-end integration (Yang and Roth, 2001). In this assay, the 5′-labeled precleaved 
oligonucleotide substrate is used as the donor DNA and a circular plasmid is the target DNA 
for integration (Fig. 3B). Two different length U5 oligonucleotide mimics were assayed: a 
20-mer and a 28-mer (Fig. 5B). The IN 1–105 domain was titrated against 1 pmol of IN 
106–404. Reaction products were resolved by agarose gels (Fig. 5B) and quantified (Fig. 
5C). The efficiency of both one-end and two-end integration reactions is reproducibly 
increased four- to fivefold in the presence of the 28 versus the 20-mer substrate (compare 
panels 20-mer and 28-mer, Fig. 5C). This result suggests that longer substrates promote a 
more efficient assembly of a catalytic competent complex and/or further stabilize the 
interactions between the domains. This is of interest, as the region between positions 20 and 
28 is outside of the conserved 13-bp inverted repeat sequence at the termini of the LTR.
Despite the efficiency differences between the 20-mer and the 28-mer U5 LTR substrate, the 
single-end and the two-end products were similar with respect to the ratios of IN 1–105 to 
IN 106–404. Preferential synthesis of two-end integration products was observed at an IN 1–
105:IN 106–404 ratio of 2:1 (lanes 3 and 9, Fig. 5B). At a molar ratio IN 1–105:IN 106–404 
of 3:1, the overall yield of products increased; however, the ratio of one-end:two-end 
integration was near stoichiometric (Fig. 5C). The two-end integration products were more 
sensitive to the presence of excess of IN 1–105 zinc-binding domain (Fig. 5B, lanes 5 and 
11). The presence of a large excess of IN 1–105 (28-fold molar excess over IN 106–404, 
Fig. 5B, lanes 6 and 12) was inhibitory to the two-end integration reaction.
The catalytic activities of the full-length, wild-type IN protein purified under the current 
scheme were also analyzed. Fig. 6A shows a titration of WT IN (1.4 to 10 pmol) in the 
presence of 0.5 pmol of a blunt-ended 20-mer oligonucleotide substrate. Maximal 3′-
processing was observed with 5 pmol of IN enzyme (lane 6), and increasing the amount of 
enzyme to 7.6 pmol or higher yielded inhibition of both 3′-processing and strand-transfer 
reactions (Fig. 6A, lanes 7 and 8).
The full-length IN enzyme was also tested in the concerted two-end integration assay (Fig. 
6B). The WT IN was titrated for strand transfer into a plasmid target DNA using a 5′-
labeled precleaved oligonucleotide substrate, and the products were analyzed by agarose 
gels. The yield of one-end and two-end products increased with respect to IN protein (lanes 
1–3), with maximal products detected at 5 pmol enzyme in the presence of 1 pmol of 28-mer 
U5 LTR substrate (lane 4). Concentrations of enzyme over this amount inhibited both the 
one-end and the two-end strand-transfer products (lanes 5 and 6). Although the one-end 
integrant remains the preferred product, the yield of two-end concerted integrants is 
improved utilizing the protein purified from the soluble fraction.
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Characterization of soluble M-MuLV IN by size-exclusion chromatography
To determine the multimerization state of M-MuLV IN, the WT and C209A IN were further 
characterized by sizeexclusion chromatography. Within M-MuLV IN, there are three Cys 
residues; two within the zinc-binding domain and the third, C209, within the catalytic core. 
Previous studies have shown that IN 106–404 bearing C209A was unable to complement IN 
1–105, indicating that the mutation affected the multimerization of IN (Jonsson et al., 1996). 
IN C209A was therefore analyzed by size fractionation. The soluble fraction of WT IN and 
C209A (Fig. 2) was purified by Ni2+-NTA affinity columns, eluted with step concentrations 
of imidazole, and pooled. WT IN and C209A IN were further concentrated and applied into 
a FPLC S200 sizeexclusion column. The elution profiles are shown in Fig. 7A. The elution 
position of the globular protein markers is indicated. No proteins were found in the void 
volume of the column (data not shown). WT IN protein eluted in a broad protein profile with 
a major peak between 150- and 66-kDa protein markers. From the standard curve, the 
calculated molecular mass of the predominant WT IN species was 95 kDa, corresponding to 
a dimer of WT IN. C209A IN protein eluted in a more limited profile with a major peak 
between 443- and 150-kDa protein markers, corresponding to a calculated molecular mass 
of 165 kDa, consistent with a tetramer of C209A IN.
Fractions from the S200 column were further analyzed for integration activity. Equivalent 
aliquots of the fractions containing IN proteins were incubated with a precleaved 5′-labeled 
28-mer oligonucleotide substrate and strand-transfer products into a plasmid DNA target 
were analyzed by agarose gels (Yang and Roth, 2001). Fig. 7B shows the profile of 
concerted strand-transfer activity from the fractions containing the WT IN protein. Although 
further assembly of protein and DNA occurs under the assay conditions, analysis across the 
S200 column identifies IN multimerization states capable of functional assembly. The peak 
of concerted strand-transfer activity is located between fractions 52 and 54 with a maximum 
yield obtained from fraction 53. Low strand-transfer activity was detected when the input IN 
into the assay consisted of fractions expected to contain tetramers (Fig. 6B, fraction 50) or 
those expected to contain monomers of WT IN (Fig. 7B, fraction 59) (data not shown). A 
profile of concerted strand-transfer activity of the fractions containing the C209A IN protein 
is shown in Fig. 7C. The peak of strand-transfer activity is concentrated between fractions 
49 and 53 with a maximum yield obtained from fraction 50, consistent with the structure of 
the input C209 IN of a tetramer. C209A IN fractions predicted to contain IN dimers 
maintained significant levels of activity for this assay (Fig. 7C, fraction 53). Fractions 
expected to be monomers are not active (fraction 59, data not shown).
Fractions resolved by exclusion chromatography were further analyzed in the 
oligonucleotide-based assays (Fig. 3A). Initial assays utilized a 20-mer precleaved substrate 
(Fig. 8A), and limiting amounts of the fraction (1 µl) were assayed for strand transfer. The 
profile of activity from fractions containing WT IN protein is shown in Fig. 8A. A single 
peak of strand-transfer activity at fraction 50 was detected under these conditions. These 
results suggest that under limiting enzyme, preassembled tetramers are active for strand 
transfer, under conditions where preassembled dimers present at higher concentrations 
(fraction 53) are not active.
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Strand-transfer activity with S200 fractions was further tested using a longer 28-mer 
precleaved substrate and the products were visualized by denaturing electrophoresis (Figs. 
8C and D). Interestingly, two different patterns of target-site utilization were observed for 
the strand-transfer products. For the WT IN S200 fractions, there is a loss of a high-
molecular-weight strand-transfer product from fractions 51 to 54 (Fig. 8C). This corresponds 
to fractions whose input IN was capable of concerted two-end integration with an exogenous 
plasmid target DNA (Fig. 7B). The large strand-transfer products result from integration at 
the end of the target DNA. These results indicate that the assembly of an active synaptic 
complex on a large target DNA within these fractions is distinct. The generation of different 
target sites was previously detected in complementation assays using IN 106–404 and IN 1–
105. A limited range of target sites were selected in the presence of a zinc-coordinated 
HHCC region versus a HHCC domain renatured in the presence of EDTA (Yang et al., 
1999a). The increase in stringency was interpreted to reflect the tightness of the assembled 
complexes in presence of Zn2+.
Similarly, two different patterns of strand-transfer products can be visualized when aliquots 
of fractions containing C209A IN mutant are assayed utilizing the 28-mer U5 LTR 
oligonucleotide (Fig. 8D). A shift to higher-molecular-weight strand-transfer products is 
observed between fractions 48 and 52, whose input IN is in the range of dimers and 
tetramers. These fractions directly correlate with those active for integration into a large 
exogenous DNA substrate (Fig. 7C). Fractions 44 to 47 (including multimers greater than 
tetramers) plus fractions 55 to 64 (including monomers) yield smaller sized strand-transfer 
products. Although similar fractions were positive for strand-transfer activity using a 20-mer 
substrate (Fig. 8B), no difference in the target-site specificity was observed. The result using 
the 28-mer was surprising. The generation of a different target site may represent a distinct 
conformation of the DNA within an active synaptic complex.
Discussion
In this study, we have purified active M-MuLV integrase proteins under nondenaturing 
conditions. Recombinant M-MuLV IN was previously purified under harsh denaturing 
conditions involving highly concentrated solutions of either guanidine chloride or urea to 
solubilize the proteins from inclusion bodies (Jonsson et al., 1993), causing protein 
denaturation. Slow renaturation by dialysis is necessary after purification, in order to refold 
the protein into an active conformation. In the current study, IN was solubilized immediately 
after bacterial lysis, by performing a series of controlled cycles of sonication at 4°C. The 
strong DNA-binding activity of retroviral IN has been previously reported (Roth et al., 
1988). After shearing the DNA, solubilized IN can be directly bound to nickel-affinity 
resins, eluted with imidazole solutions, and further purified by heparin columns. A similar 
scheme of lysis was previously used to purify GST-tagged M-MuLV IN by using 
glutathione–agarose resins (Dotan et al., 1995). In that report, for consistent activity between 
different preparations, a phosphocellulose column was necessary to remove an inhibitor 
(Dotan et al., 1995). Using the purification scheme described herein, individual fractions 
eluted with imidazole could be directly monitored for IN activity. A similar scheme of lysis 
and solubilization was used to purify an active two-domain derivative of RSV IN (Yang et 
al., 1999b), feline immunodeficiency virus (FIV) IN (Shibagaki et al., 1997), HTLV-2 IN 
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(Pieper and Jonsson, 2002), and Sin Nombre virus N protein (Jonsson et al., 2001). Other 
alternative approaches to purify retroviral INs include solubilization from insoluble fractions 
with 1 M NaCl solutions for HIV-1 IN (Sherman and Fyfe, 1990) and RSV PrA IN (McCord 
et al., 1998).
Retroviral INs have been modified by site-directed mutagenesis in order to improve their 
solubility. In an HIV-1 IN study, 29 point mutants were tested in which hydrophobic 
residues were substituted with Lys or Ala residues (Jenkins et al., 1995). The single point 
mutation of F185K within the catalytic core improved the solubility of the HIV-1 
polypeptide. A single point mutation of F199K for the RSV two-domain integrase (Hyde et 
al., 1999) and F185H for SIV IN was also found to improve solubility and the ability to 
obtain diffraction quality crystals (Li et al., 1999). Both of these residues are located at the 
dimer interface of the catalytic core domain. A similar approach was developed with an N-
terminal truncated construct of M-MuLV RT, to modify potentially solvent exposed 
hydrophobic residues. Of the substituted enzymes, V433K and L435K were substantially 
more soluble in the absence of detergent than the parental construct and crystals of the N-
terminal truncated M-MuLV L435K RT complexed with a duplex of DNA oligonucleotides 
have been obtained (Das and Georgiadis, 2001). In the present study, we have targeted four 
positions at the C terminus within the catalytic domain of M-MuLV IN for mutagenesis. 
Substituted amino acids were found to be structurally equivalent to those previously altered 
in HIV-1, RSV, and SIV IN that had improved the solubility of the polypeptides. 
Additionally, we used the previously generated M-MuLV IN point mutant, within the 
catalytic triad C209A IN, which was known to be active in vitro for 3′-processing, strand-
transfer, and disintegration reactions (Donzella et al., 1998; Jonsson et al., 1996). Among the 
mutants tested, C209A IN yielded twofold increase in the soluble fraction with respect to the 
parental WT IN. Using the expression and purification schemes presented herein, active and 
highly purified C209A IN is under intense research in order to obtain diffraction quality 
crystallization conditions as a model for the full-length M-MuLV IN structural analysis.
There are several signs that the proteins purified from the soluble fractions are greatly 
improved over renatured preparations in solubility and activity. Previously, the renatured 
protein did not chromatograph on DEAE, heparin butyl sepharose, or sephadex 75 as a 
homogenous peak (Jonsson and Roth, unpublished results). On many resins, including 
Superose 12 columns, the protein never eluted. From the results presented on Fig. 4B, the 
native protein fractionated on the FPLC– heparin column as a symmetric peak. The stability 
of both WT IN and C209A IN allowed the fractionation and activity profiles using size-
exclusion chromatography. Previously purified preparations of IN 106–404 recovered from 
the insoluble fraction were sensitive to high DTT concentrations for full complementation 
activity with IN 1–105 (Donzella et al., 1996; Jonsson et al., 1996), suggesting improper 
refolding and low stability in solution. The activities of IN 106–404 varied widely between 
different preparations and frequently yielded inactive protein. With the purification 
conditions developed herein, the ability to obtain active IN 106–404 has been highly 
reproducible.
The irreproducibility of the proteins purified from the insoluble fraction makes direct 
comparison difficult with the current soluble preparations. However, published data on 
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previously optimized proteins purified from the insoluble fractions indicate that the soluble 
IN 1–105, IN 106–404, and WT IN require, under standard reaction conditions, a lower 
protein:protein as well as protein:DNA ratio for 3′-end processing and strand-transfer 
reactions compared with the renatured proteins. Previously a 10-fold molar excess of IN 1–
105 to IN 106–404 was required for optimal strand-transfer and 3′-processing (Yang et al., 
1999a), whereas a 2.3:1 ratio was optimal for the soluble proteins. Similarly, concerted two-
end integration previously required an optimal molar ratio of IN 1–105: IN 106–404 of 8:1 
(Yang and Roth, 2001), whereas with the soluble protein, a 2:1 ratio yielded predominantly 
two-end concerted integration products. Using the soluble wild-type IN, the optimal 
IN:DNA ratio was 10:1. Using the same assay, M-MuLV IN protein purified from insoluble 
fractions followed by slow steps of renaturation required a 20:1 ratio of IN:DNA for optimal 
integration (Jonsson et al., 1996). Similarly, optimal two-end integration using a 28-mer LTR 
was obtained with the soluble IN at an IN:LTR ratio of 5:1, whereas previously the maximal 
integration into an exogenous substrate required a 20:1 IN:LTR ratio, with the predominant 
product being the one-end integrant (Yang and Roth, 2001).
In an infected cell, the two ends of the viral DNA must be integrated into the target host 
DNA in a concerted reaction, and multiple lines of evidence suggest that integrase functions 
as a multimer to act on both DNA ends. As previously determined, in solution, both RSV 
and HIV-1 IN existed as a mixture of monomers, dimers, and tetramers in equilibrium (Jones 
et al., 1992; Vincent et al., 1993). Multimerization is stimulated by Zn2+ (Lee et al., 1997), 
Mn2+ (Wolfe et al., 1996), and high-molecular-mass complexes were detected in the 
presence of fluorescent oligonucleotides and Mg2+ (Vercammen et al., 2002). Protein cross-
linking experiments have also shown that IN exists as a multimer (Heuer and Brown, 1997, 
1998). Furthermore, multimerization during catalysis is implied by studies indicating 
complementation between HIV-1 IN mutants (Engelman et al., 1993; vanGent et al., 1993) 
and functional tetramers were deduced from kinetic studies of disintegration of ASV IN 
(Bao et al., 2003). The structure of a full-length retroviral IN is not yet known. However, the 
central catalytic core domain and all two-domain fragments spanning the core plus either the 
C terminus (Chen et al., 2000a; Yang et al., 2000) or the N terminus (Wang et al., 2001) 
from different retroviruses form dimers in the crystal structures. Similarly, the structure of 
the Tn5 transposase synaptic complex consists of a dimer subunit (Davies et al., 2000). 
Alternatively, tetramers have been isolated from cells expressing HIV-1 IN (Cherepanov et 
al., 2003), also detected under reducing conditions when HIV-1 IN was analyzed by 
fluorescence anisotropy decay measurements (Deprez et al., 2000) and by a Zn2+-dependent 
interaction that requires the zinc finger motif in the amino-terminal domain (Lee et al., 
1997). Previously, biochemical characterization of M-MuLV IN was restricted due to the 
limited solubility of the recombinant protein. In the present study, the multimerization state 
of M-MuLV IN was functionally analyzed. WT IN was shown to migrate predominantly as a 
dimer on size-exclusion chromatography, consistent with other retroviral IN systems. 
Functional analysis indicated that fractions in equilibrium between dimers and tetramers are 
capable of assembly and catalysis of two viral LTRs into an exogenous target DNA. No 
differences were observed in the target-site selection of the strand-transfer products when a 
20-mer U5-end substrate was assayed across the gel filtration column. Significant 
differences in the target-site selection were observed when the column was assayed with a 
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28-mer U5 substrate for strand transfer. With both 20-mer and 28-mer U5 substrates, 
multimers larger than tetramers and smaller than dimers were shown to be active as well. 
However, the dimers and tetramers could be differentiated from the other multimers in an 
assay by a distinct strand-transfer profile and target-site selection, indicative of a different 
assembly pathway. Similar results were obtained when fractions containing C209A IN were 
assayed. Although C209A IN migrated predominantly as a tetramer, the peaks of activity 
were also mainly concentrated on fractions expected to contain dimers–tetramers. These 
results indicate that multimerization mediated by protein–protein interactions is different 
than functional multimerization during catalysis, in the presence of a DNA substrate.
The first step in the integration pathway involves the assembly of a stable complex between 
IN and the viral DNA donor substrate. HIV-1 IN assembled on immobilized substrates was 
shown to be sufficient to catalyze strand transfer when the target DNA was added 
subsequent to assembly (Wolfe et al., 1996). Studies using the HIV-1 IN strand-transfer 
inhibitors diketo acids (DKAs) indicated that the target DNA requires a configuration of the 
enzyme defined only after the assembly of the specific IN complex (Espeseth et al., 2000). 
The results presented in Fig. 8 suggest that upon assembly on identical 28-mer 
oligonucleotide DNA substrates, the target DNA can be positioned within the active 
complex in at least two distinct configurations, as revealed by their distinct target DNA site 
selection. Using the same donor 28-mer U5 DNA substrate but a large plasmid DNA (Fig. 
7B), we demonstrated that the same fraction which migrated on the S200 as dimers through 
tetramers were able to perform concerted integration, which is indicative of a functional and 
coordinated nucleoprotein assembly. Previous results have indicated that plasmid target 
DNA can access the target binding site and promote the functional and coordinated assembly 
of the multimer, stabilizing the subunits, in a concerted integration assay (Yang and Roth, 
2001). Fractions other than dimers–tetramers were not correctly stabilized by the plasmid 
target DNA since no strand transfer on the exogenous plasmid could be detected. Substrate 
coordination features were also analyzed with M-MuLV disintegration reactions (Donzella 
et al., 1996). Mispairing of the crossbone single-strand region of the substrate affected the 
intermolecular, but not the intramolecular disintegration reactions, suggesting differential 
assembly for cis or trans half-site modes of substrate binding (Donzella et al., 1996). It is not 
known whether these different configurations are ultimately defined by protein–protein 
and/or DNA–protein interactions. As proposed by Sinha et al. (2002), within the population 
only a minority of the HIV-1 IN subunits will correctly interact to form a nucleoprotein 
complex competent for concerted integration. Most of the interactions will lead to one-end 
integration events.
The analysis of complementation assays of IN 1–105 with IN 106–404 M-MuLV IN 
nonoverlapping constructs indicated a more efficient assembly of multimeric complexes 
(four- to fivefold) when using 28-mer versus 20-mer oligonucleotide substrates mimicking 
the viral terminal U5 in a concerted integration reaction (Fig. 5B). Interestingly, positions 20 
to 28 are outside of the conserved 13-bp inverted repeat sequences at the termini of the M-
MuLV LTR. For HIV-1 IN, the extension of 13 nucleotides on the 15 terminal bases IN 
recognition sequence enhanced 3′-processing of the termini in an oligonucleotide-based 
assay (Vink et al., 1991). Reconstitution systems have also used purified IN and linear 
retrovirus-like LTRs to recapitulate concerted two-end integration reactions (about 500-bp-
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long) for HIV-1 (Hindmarsh et al., 1999) and RSV (McCord et al., 1998). For RSV, as well 
as in vivo for HIV-1 (Brown et al., 1999) and M-MuLV (Murphy and Goff, 1992), deletions 
or modifications of internal sequences (up to 12 nucleotides from the end) have major effects 
in avian LTRs to promote two-end integration in vitro (Chiu and Grand-genett, 2000). The 
role of either the sequence or the structure of nucleotides outside of the terminal sequences 
is not clear. A 22-bp deletion starting at position 12 from the M-MuLV LTR end has little 
effect on IN-associated properties in the preintegration complexes (Wei et al., 1998). For 
SIV IN, two-end integration events showed an increase in efficiency with an increase in the 
length of the donor DNA from 134 to 433 bp (Goodarzi et al., 1999). For HIV-1, positions 
17–20 were found to be required for concerted integration (Brin and Leis, 2002). However, 
preliminary results indicate that position 20 of the M-MuLV U5 substrate tolerates any 
nucleotide when assayed in the complementation assay for concerted integration (data not 
shown). More studies are necessary to define the role of the outside sequences in recognition 
by retroviral integrases.
Material and methods
Materials
Crude [γ-32P]ATP (7000 Ci/mmol) was purchased from ICN. T4 polynucleotide kinase, T4 
DNA ligase, Vent DNA polymerase and restriction enzymes were obtained from New 
England Biolabs. Ni2+-nitrilotriacetic acid agarose (Ni2+-NTA) was purchased from Qiagen. 
Ni2+-NTA Su-perflow (5 mL) and HiTrap heparin HP (5 ml) were purchased from 
Amersham Biosciences.
Oligonucleotides
DNA oligonucleotides were prepared by the University of Medicine and Dentistry of New 
Jersey, DNA Synthesis Facility and purified by electrophoresis on 20% denaturing 
polyacrylamide gels (Jonsson et al., 1993). Oligonucleotides used in this study were labeled 
with [γ-32P]ATP by a kinase reaction as previously described (Jonsson et al., 1993). 
Oligonucleotide 5319 (28-mer) 5′-GACTACCCGT-CAGCGGGGGTCTTTCATT-3′ and its 
complementary strand 5321 5′-AATGAAAGACCCCCGCTGACGGGTA-GTC-3′ or 
oligonucleotide 2783 (20-mer) 5′-GTCAG-CGGGGGTCTTTCATT-3′ and its 
complementary strand 2785 5′-AATGAAAGACCCCCGCTGAC-3′ were used as the blunt-
end U5 end substrate for the 3′-processing reactions. Oligonucleotide 5320 (26-mer) 5′-
GACTACCCGT-CAGCGGGGGTCTTTCA-3′ and its complementary strand 5321, or 
oligonucleotide 2784 (18-mer) 5′-GTCAGCG-GGGGTCTTTCA-3′ and its complementary 
oligonucleotide 2785 mimicking a precleaved U5 end, were used as the substrate for strand-
transfer and two-end integration reactions.
Generation of IN point mutants
Point mutations in M-MuLV IN were generated by overlapping PCR. For the 
oligonucleotides shown below, underlined positions indicate the codon changed. For 
individual PCR reactions, the first fragment was obtained with a common 5′ primer 5′-
GATCACCGGTTTTCATTACACAGT-GACTGATA-3′ (100 pmoles) and with 5′-
CAGGGCTA-AGGGGAGTTGGAGCACCCAGTCTCT-3′ (for L244Q, 100 pmol), 5 ‘-
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GCCCGGCGTGTTGCGCTTTCGGTACA-GGGCTA-3′ (for A252K, 100 pmol), 5′-
GCCCGGCGT-GTTGCGGTGTCGGTACAGGGCTA-3′ (for A252H, 100 pmol) or 5′ -
ATGGGGGCCCGGCGTCTTGCGGGCTGC-GTACAG-3′ (for N254K, 100 pmol) on the 
template pET-HTWT (Jonsson et al., 1993) and Vent DNA polymerase. Cycle conditions 
were as follows: 2 min at 95°C, 35 cycles of 30 s at 95°C, 30 s at 63°C and 90 s at 68°C, and 
a final incubation of 10 min at 68°C. A 750-bp fragment in each case was gel-isolated. The 
second PCR fragment was obtained with 5′ -AGAGACTGGGTGCTCCAACTCCCCT-
TAGCCCTG-3′ (for L244Q, 100 pmol), 5′-TAGCCCTG- 
TACCGAAAGCGCAACACGCCGGGC-3′ (for A252K, 100 pmol), 5′ -
TAGCCCTGTACCGACACCGCAACACG-CCGGGC-3′ (for A252H, 100 pmol), or 5′-
CTGTACCG-AGCCCGCAAGACGCCGGGCCCCCAT-3′ (for N254K, 100 pmol), each 
one incubated with a common 3′ primer 5′-GGTGGATCCAGTACTGACCCCTCTG-3′ 
(100 pmol) using template pET-HTWT and Vent DNA polymerase as described above. A 
500-bp fragment in each case was gel-isolated. For overlapping PCR reactions, equimolar 
amounts of the 750 bases fragment and 500 bases fragment for each mutant were incubated 
with the 5′ and 3′ common primers (100 pmol each) and Vent DNA polymerase. Cycle 
conditions were as follows: 2 min at 95°C, 35 cycles of 30 s at 95°C, 30 s at 53°C, 3 min at 
68°C, and a final incubation of 10 min at 68°C. The 1.2-kb product fragments were digested 
with SacII and BamHI (contained within 3′ primer). For each construct, an 890-bp 
fragments was gel-isolated and exchanged into pET-HTWT. Introduction of the single point 
mutations were verified by sequencing with the 3′ common primer at the Core DNA 
Facility, UMDNJ/ RWJMS.
Expression and purification of M-MuLV integrase
Previously reported expression vectors for recombinant M-MuLV IN (pET-HTWT wild 
type) (Jonsson et al., 1993), IN C209A (Jonsson et al., 1993), IN 106–404 (Jonsson et al., 
1993), and IN 1–105 (Yang et al., 1999a) containing a hexahistidine tag were expressed in 
Escherichia coli BL21 (DE3) (Novagen). A similar procedure has been recently reported for 
HTLV-2 IN (Pieper and Jonsson, 2002). For each construct, 100 mL of Luria broth medium 
(LB) containing 200 µg/mL Carbenicillin (LB-Carb200) was inoculated and grown overnight 
at 37°C with constant shaking. Cultures were then centrifuged, resuspended into 20 mL of 
LB-Carb200, and used to inoculate 1 L of LB-Carb200 in a 2-L flask. Cultures were grown 
for 2 h at 30°C, induced with IPTG (0.256 mM) for 2 h at 30°C, and resuspended into 40 
mL of ice-cold solubilization buffer (50 mM sodium phosphate buffer, pH 8.0, 300 mM 
NaCl, 10 mM imidazole, 10 mM Chaps (3-[(3-cholamidopropyl)dimethylammonio]-1-
propane sulfonate), 1 protease EDTA-free tablet (Boehringer Mannheim) per 50 milliliters 
of buffer, at 4°C. One hundred milligrams of lysozyme was added, dounced until mixed, and 
kept at 4°C for 15 min. Samples were then sonicated for 15 s and placed on ice for 1 min. 
Sonication was repeated until samples appeared clear (not viscous) and then they were 
centrifuged at 16,000 rpm in a Sorvall SS34 rotor for 1 h at 4°C. Supernatants containing 
soluble IN proteins were subjected to purification either by batch purification or using 
columns on FPLC systems.
(i) Batch purification—Solubilized extracts (40 mL) were mixed with 1 mL of Ni2+-NTA 
preequilibrated in solubilization buffer, and incubated overnight at 4°C with rocking. 
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Decanted resin was washed with 100 mL of washing buffer (50 mM sodium phosphate, pH 
8.0, 1 M NaCl, 25 mM imidazole, 10 mM Chaps, 10 mM 2-mercaptoethanol, 20% glycerol). 
Step elution (1-mL fractions) was performed with 5 mL each of washing buffer containing 
50, 100, 250, 500 mM imidazole. Elution of the specific IN proteins and subdomains varied 
between 50 and 250 mM imidazole, as indicated. IN proteins or subdomains after one round 
of batch purification were active and suitable for biochemical studies. Fractions were pooled 
and dialyzed against 20 mM Hepes, pH 7.4, 1.5 mM DTT, 400 mM KCl, 2 mM Chaps, 50% 
glycerol, and 10 µM ZnCl2 and stored at −80°C.
(ii) FPLC-based purification—Five milliliters of Ni2+-NTA column-FPLC was 
sequentially equilibrated with 7 column volumes of buffer A (50 mM sodium phosphate, pH 
8.0, 1 M NaCl, 10 mM Chaps, 5 mM 2-mercaptoethanol, and 10% glycerol) with 10 mM 
imidazole, with 7 column volumes of buffer A containing 25 mM of imidazole, and with 7 
column volumes of buffer A with 10 mM imidazole. Solubilized extracts containing WT 
full-length IN were filtered through 0.45-µm filters and applied to the column. Bound 
proteins were washed with 8 column volumes of buffer A containing 25 mM imidazole or 
until baseline and then eluted with 9.4 column volumes of a 10 to 500 mM imidazole 
gradient in buffer A, collecting 2.5-mL fractions. Aliquots of the fractions were analyzed by 
SDS–PAGE and for strand-transfer activity in an oligonucleotide-based assay (see below). 
Selected fractions were pooled and diluted to 0.4 M NaCl with buffer C (50 mM Hepes pH 
7.4, 1 mM DTT, 2 mM Chaps, 10% glycerol). The heparin column–FPLC (5 mL) was 
sequentially equilibrated with 4 column volumes of buffer C containing 0.4 M NaCl, with 2 
column volumes of buffer C containing 2 M NaCl and, with 5 0.4 M NaCl, with 2 column 
volumes of buffer C containing 2 M NaCl and, with 5 the Ni2+-NTA column were loaded 
onto the heparin column and eluted with 7 column volumes of a 0.4 to 2 M NaCl gradient in 
buffer C (2.5-mL fractions). Aliquots of the fractions were analyzed by SDS-PAGE and for 
strand-transfer activity in an oligonucleotide-based assay (see below).
Size-exclusion chromatography
Solubilized extracts of WT IN and C209 IN (corresponding to 2 L of culture) were bound in 
batch to 2 mL of Ni2+-NTA resin and step-eluted with 5 mL of washing buffer containing 
100 and 250 mM imidazole and dialyzed at 4°C for 6–8 h against 50 mM Hepes, pH 8.0, 1 
M NaCl, 1.5 mM DTT, 2 mM Chaps, 10 µM ZnCl2, and 10% glycerol. Proteins were 
concentrated to 250 µL by centricon columns (YM-10: 10,000 molecular weight cut-off); 0.5 
mg of each IN protein (250 µL) was applied to a S200 10/30 gel filtration column 
(Pharmacia) preequilibrated with 50 mM Hepes, pH 8.0, 400 mM KCl, 1.5 mM DTT, 2 mM 
Chaps, and 10% glycerol; 0.275-mL fractions were collected. The column was standardized 
using gel filtration molecular weight markers (Sigma): thyroglobulin (669 kDa), apofer-ritin 
(443 kDa), alcohol dehydrogenase (150 kDa), bovine serum albumin (66 kDa), and carbonic 
anhydrase (29 kDa).
Integration assays
3′-processing and strand-transfer reactions contained 0.5 pmol of labeled substrate and 
reaction buffer containing 20 mM morpholineethanesulfonic acid (MES, pH 6.2), 100 mM 
KCl, 10 mM MnCl2, 10 mM DTT, and 10% glycerol, unless otherwise indicated (Jonsson et 
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al., 1993). The reaction conditions (35 µL) for two-end integration reactions (Yang and Roth, 
2001) were the same as those for 3′-processing and strand-transfer reactions except that 200 
mM KCl was added in the presence of 1 pmol of U5 substrate and 1.2 µg of target plasmid 
DNA. Oligonucleotide substrates were labeled at the 5′ end by T4 polynucleotide kinase 
and mixed with the complementary strand at a ratio of 1:2 (labeled oligonucleotide vs 
complementary strand) in 100 mM NaCl. The oligonucleotides were annealed by heating for 
3 min at 95°C and then cooled to room temperature. Complementation assays were 
performed by preincu-bating the IN 1–105 with the U5 substrate for 5 min on ice. IN 106–
404 was added, followed by incubation at 37°C for 5 min. When assaying the full-length IN 
protein, the U5 LTR substrate was preincubated with aliquots of the protein for 5 min on ice 
followed by addition of target DNA plasmid and KCl and the reactions were incubated at 
37°C for 2 h. Reactions were stopped by the addition of 10 mM EDTA (pH 8.0)-0.5% SDS 
and 100 µg/mL of proteinase K at 37°C for 1 h. Reaction products were visualized by 
electrophoresis on a 1% agarose gel and autoradiography of dried gels.
Western blot
Western blots were performed using anti-MuLV IN antibody (rabbit 4, bleed 5) (Tanese et 
al., 1986).
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Fig. 1. 
(A) Illustration of IN proteins used in this study. The name of each construct is indicated to 
the left of each protein. (B) Solubility of the point mutants generated on the full-length M-
MuLV IN protein; 0.005% of the soluble fraction (1 mL) for each mutant protein was loaded 
on SDS–PAGE and analyzed by Western blotting with anti-IN antibody (Tanese et al., 
1986). Migration of molecular weight markers are indicated.
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Fig. 2. 
Purification scheme. Major steps in order to obtain soluble fraction are shown. Below, the 
two procedures to obtain purified M-MuLV IN proteins. Left: Proteins bound to Ni2+-NTA 
beads are eluted with the indicated solutions of imidazole. Right: Proteins bound to Ni2+-
NTA column/FPLC system are eluted with an imidazole gradient running between the 
indicated concentrations. Pooled proteins are then loaded into a heparin column/FPLC 
system and eluted with a NaCl gradient running between the indicated concentrations.
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Fig. 3. 
(A) Integration assays based on oligonucleotide 5′-labeled substrates. 3′-processing and 
strand-transfer reactions are indicated. (B) Concerted two-end integration assay. Target DNA 
and the two major types of reaction products are shown. The third product (not indicated) is 
identical to that shown in (A).
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Fig. 4. 
Activity column profiles from Ni2+-NTA/FPLC (A) or from heparin column/FPLC system 
(B). Fractions were assayed for strand-transfer activity (upper panels) and SDS-PAGE and 
Coomassie staining (lower panels). (C) M-MuLV IN proteins purified using batch elution. 
Lane 1, IN 1–105; lane 2, IN 106–404; lane 3, C209A IN; lane 4, WT IN.
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Fig. 5. 
Complementation assays of purified IN 1–105 and IN 106–404. (A) 3′-processing and 
strand-transfer reactions using 0.5 pmol of a blunt-end 20-mer-labeled oligonucleotide-based 
assay. IN 106–404 (1 pmol) was incubated alone (lane 3), or in the presence of IN 1–105 at 
2.3 pmol (lane 4), 4.6 pmol (lane 5), 9.2 pmol (lane 6), 13.8 pmol (lane 7), 27 pmol (lane 8), 
and 55 pmol (lane 9). Products were resolved by 16% sequencing gels. Lanes 1 and 2 
correspond to reactions in the absence of presence of 5 pmol of purified WT IN protein, 
respectively. (B) Concerted two-end integration assay; 1 pmol of IN 106–404 IN was 
assayed with increasing amounts of IN 1–105 using a 20-mer (lanes 1–7) or with a 28-mer 
(lanes 8–14) donor-labeled substrate and a target DNA. Reactions products were resolved by 
agarose gels and the radioactive bands quantified as shown in (C).
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Fig. 6. 
Integration assays of purified M-MuLV IN. (A) 3′-processing and strand-transfer reactions 
in an oligonucleotide-based assay; 0.5 pmol of blunt-end-labeled 20-mer substrate was 
incubated with increasing amounts of purified IN: 1.26 pmol (lane 3), 2.52 pmol (lane 4), 
3.8 pmol (lane 5), 5 pmol (lane 6), 7.6 pmol (lane 7), and 10 pmol (lane 8). Reaction 
products were resolved on 16% sequencing gels, dried, and exposed. (B) Concerted two-end 
integration; 1 pmol of a 28-mer-labeled substrate was incubated with increasing amounts of 
purified WT IN: 0.63 pmol (lane 1), 1.26 pmol (lane 2), 2.52 pmol (lane 3), 5 pmol (lane 4), 
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7.6 pmol (lane 5), and 10 pmol (lane 6) and with the target DNA for 1 h at 37°C. Reaction 
products were resolved by 1% agarose gels and the dried gels exposed to films.
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Fig. 7. 
Chromatographic resolution of M-MuLV integrase proteins. (A) Elution profile of WT IN 
and C209A IN on S200 gel filtration chromatography. The relative position of migration of 
the globular molecular weight markers is indicated. The volume of each fraction was 275 
µL. Inset: Migration is plotted vs the molecular weight of the markers. Dotted lines show 
molecular weight of fractions 50 and 53. The profile shows only fractions containing 
proteins. Aliquots (1 µL) of the fractions of WT IN (B) or C209A IN (C) were assayed in the 
concerted two-end integration assay, using a 28-mer 5′-labeled oligonucleotide donor 
substrate and target plasmid DNA as acceptor.
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Fig. 8. 
(A, B) Strand-transfer activity of the S200 chromatography fractions using a 20-mer 
oligonucleotide substrate. (A) Activity profile of WT IN assayed at 1 µL across the fractions. 
(B) Activity profile of C209A IN assayed at 2 µL across the fractions. Reaction products 
were resolved by 16% sequencing gels. (C, D) Strand-transfer activity of the exclusion 
chromatography fractions using a 28-mer oligonucleotide substrate. WT IN was assayed 
using aliquots (2 µL) of the fractions (C) or C209A IN (C). Reaction products were resolved 
by 16% sequencing gels.
Villanueva et al. Page 28
Virology. Author manuscript; available in PMC 2017 October 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
